A pteridine 7 (8H) -ketone compound and its pharmaceutical application

Through the targeting of CDK2 by the novel pteridine 7(8H)-keto compounds, the problems of toxic and side effects and drug resistance of existing CDK2 inhibitors have been solved, efficient and specific CDK2 inhibition have been achieved, and safer cancer treatment methods have been provided.

CN115010711BActive Publication Date: 2024-12-03JIANGNAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210816319.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-07-12
Publication Date
2024-12-03
Estimated Expiration
2042-07-12

AI Technical Summary

Technical Problem

Existing CDK2 inhibitors have major toxic side effects and drug resistance problems in the treatment of cancer, and lack specificity, making it difficult to meet clinical needs.

Method used

Develop a novel pteridine 7(8H)-keto compound as a CDK2 inhibitor to provide a more specific and less toxic side effect treatment pathway through excellent CDK2 inhibitory activity, including general formula (I) and general formula (II) pteridine 7(8H)-one derivatives and their stereoisomers or pharmaceutically acceptable salts are used to target CDK2 to inhibit its activity.

Benefits of technology

This compound exhibits efficient CDK2 inhibitory activity, is selective and has wide application prospects, can effectively inhibit cancer cell proliferation and induce apoptosis, providing a safer therapeutic option.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115010711B_ABST
    Figure CN115010711B_ABST
Patent Text Reader

Abstract

The present invention discloses a pteridine 7 (8H) ketone compound and its pharmaceutical application, belonging to the field of medicine. The pteridine 7 (8H) ketone derivative or its stereoisomer or its pharmaceutically acceptable salt has a structure shown in the general formula (I) or (II), has good inhibitory activity on CDK2 kinase, has a certain degree of anti-tumor cell proliferation effect on HCT 116 and MV4-11 cell lines, can provide a reference for the study of CDK2 small molecule inhibitors, and has a very broad application prospect. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a pteridine 7(8H)-one compound and its pharmaceutical application, belonging to the field of medicine. Background Art

[0002] Cancer is one of the most serious life-threatening diseases, with complex causes. Genetic factors, leading to genetic damage or mutation, as well as environmental factors, can all contribute to its development. Cancer treatments can be categorized into traditional therapies, represented by radiotherapy, chemotherapy, surgery, or a combination of these three, and modern therapies, represented by targeted therapies and immunotherapy. While the effectiveness of traditional treatments has improved over the past few decades with advances in science and technology, their clinical application is limited by significant side effects, poor patient tolerance, and adverse prognostic factors. Consequently, research continues to focus on developing clinical drugs with more specific effects and fewer side effects. In-depth research and understanding of cancer pathogenesis has led to the emergence of targeted therapies that specifically target key cancer proteins. Traditional chemotherapy typically targets rapidly proliferating cancer cells by interfering with cell division, but this also nonspecifically targets rapidly dividing healthy cells, leading to well-known side effects. Molecularly targeted therapy, a revolutionary approach, aims to block specific biotransduction pathways or key cancer proteins involved in tumor growth and progression, interfering with cell cycle regulation or inducing cell death to achieve anti-tumor effects. Drugs used for molecular targeted therapy are primarily categorized as small molecules, monoclonal antibodies, immunotherapy cancer vaccines, and gene therapy. Molecularly targeted drugs typically exhibit distinct functions and properties. Depending on their target, they act on cell surface antigens, growth factors, receptors, or signal transduction pathways to regulate cell cycle progression, apoptosis, metastasis, or angiogenesis. Therefore, identifying ideal targets is crucial for the successful development of molecular targeted cancer therapy. Research and understanding of the mechanisms of tumor development and progression have been continuously deepened to the molecular and genetic levels, resulting in a diverse and growing list of targets for molecular targeted therapy, including cell cycle proteins, growth factors, signaling molecules, apoptosis regulators, and pro-angiogenic molecules.

[0003] The cell cycle, a fundamental process in cellular life, is regulated by a variety of protein molecules. The most prominent pathological manifestation of cancer is cell cycle dysfunction, leading to uncontrolled cell differentiation and apoptosis, resulting in unlimited cell proliferation. With the in-depth study and understanding of the molecular mechanisms of cell cycle regulation, cyclin-dependent kinases (CDKs), which promote cell cycle transitions, have become key targets for cancer therapy, among the many targets involved in regulating the tumor cell cycle.

[0004] As a member of the CDK family, cyclin-dependent kinase 2 (CDK2) binds to cyclins and directly participates in cell cycle regulation. In eukaryotic cells, CDK2 is a key cell cycle regulator; during the G1 / S phase, the retinoblastoma protein (pRb), which inhibits the transcriptional activity of transcription factors (E2Fs), is a key substrate of CDK2. In late G1 (after restriction enzyme cleavage sites), the activated CDK2-cyclin E complex and the CDK4 / 6-cyclin D complex work together to phosphorylate pRb, releasing and activating E2Fs, which initiates transcription of genes required for S phase. Throughout S phase, the CDK2-cyclin A complex and the CDK1-cyclin A / B complex continue to maintain pRb phosphorylation, ensuring cell cycle progression. As cells prepare to exit S phase, CDK2 binds to cyclin A and phosphorylates and inactivates the transcription factors E2Fs, thereby preventing apoptosis triggered by continued E2F activity. In addition to pRb, CDK2 controls the phosphorylation of multiple transcription factors, including SMAD3, FOXM1, FOXO1, upstream binding factors (UBFs), and the Myc proto-oncoprotein, which are involved in cell cycle progression at various levels. In addition to these cell cycle targets, CDK2 is also involved in mammalian DNA replication, adaptive immune responses, cell differentiation, and apoptosis. Accumulating evidence indicates that CDK2 is a key regulator of multiple oncogenic signaling pathways. CDK2 is overexpressed in approximately 86% of cancers, including liver, gastric, breast, colon, leukemia, and prostate cancers. Studies of various human cancers with specific molecular signatures that are sensitive to CDK2 inhibition have revealed CDK2 as a promising therapeutic target. For example, CDK2 has been shown to be a therapeutic target in ovarian cancer cells overexpressing cyclin E1, neuroblastoma cells with MYCN amplification, lung cancer cells with KRAS mutations, and various cancer cells with FBW7 mutations and cyclin E1 overexpression. In B-cell lymphoma and glioblastoma, CDK2 is highly expressed and essential for tumor cell proliferation. In studies related to prostate cancer, it was found that CDK2 is significantly associated with the metastasis of cancer cells. CDK2 can also play a role in the development of breast cancer by phosphorylating and activating kinase receptors. Inhibition of CDK2 can induce differentiation in primary samples and cell lines of AML patients. In the normal ubiquitination process in which cyclin D participates as a target for proteasome degradation, the ubiquitin ligase (E3) uses the AMBRA1 protein as its substrate receptor. In human tumor cells, the AMBRA1 protein often mutates. Maiani E et al. demonstrated through a series of molecular biology, cell biology, and genetic experiments that the loss of the AMBRA1 protein leads to an increase in cyclin D levels and promotes the formation of the cyclin D-CDK2 complex.Over time, the anti-cell proliferation effects of marketed CDK4 / 6 inhibitors have inevitably been limited by primary and acquired drug resistance. However, recent studies have shown that CDK2 binds to cyclin E and cyclin D to form a complex that activates downstream signaling pathways as a compensatory mechanism. In theory, specifically targeting CDK2 could achieve anti-tumor cell proliferation effects. These findings clearly demonstrate that CDK2 is an important target for anti-tumor drug research.

[0005] In-depth research and understanding of CDK2's structure and function, coupled with the recent discovery of its potential to overcome resistance to CDK4 / 6 inhibitors, have significantly advanced the design and development of small-molecule targeted CDK2 inhibitors. While no specific targeted CDK2 inhibitors have yet been officially approved for marketing, several are in clinical development. Most of these CDK2 inhibitors are non-selective, ATP-competitive inhibitors, primarily targeting the ATP-binding site of CDK2, competing with ATP for CDK2 binding, thereby inhibiting its activity and effectively preventing tumor cell proliferation or promoting apoptosis. Representative agents include aminopurines, pyridopyrimidines, aminopyrazoles, and pyrazoloquinazolines, all of which have demonstrated promising results in cancer treatment. Additionally, numerous compounds, primarily purines, thiazoles, and indoles, are in preclinical development and exhibit highly selective CDK2 inhibitory activity.

[0006] Given the importance of CDK2 activity in cell cycle regulation and the key role of this signaling pathway in the development and progression of cancer, targeted inhibition of CDK2 activity has become a potential therapeutic approach. To better meet clinical needs and treat cancer, it is necessary to develop new CDK2 inhibitors with better efficacy and lower toxicity. Summary of the Invention

[0007] In order to solve the above problems, the present invention will provide a CDK2 inhibitor with a novel structure, and discover that compounds with such a structure exhibit excellent effects and functions, providing more therapeutic approaches for cancer treatment.

[0008] The first object of the present invention is to provide a pteridine 7(8H)-one derivative having a structure represented by general formula (I) or general formula (II) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.

[0009] or

[0010] wherein R1 and R1′ are independently selected from unsubstituted or halogen-substituted C1-C8 straight or branched alkyl groups, and unsubstituted or halogen-substituted C3-C6 cycloalkyl groups;

[0011] R2 is hydroxy, methoxy, -NHR a ,or R a is H, C1-8 alkyl, NH2; R4' is C1-C8 alkyl, C1-C8 alkyl-substituted primary or secondary amino, C3-C6 cycloalkyl;

[0012] R3 and R3' are independently selected from -NHR b 、 R b is H, C1-8 alkyl, NH2; R4 and R4' are independently selected from C1-C8 alkyl, C1-C8 alkyl substituted primary or secondary amino, C3-C6 cycloalkyl.

[0013] In one embodiment of the present invention, R1 and R1' are preferably independently butyl, pentyl, pyranyl, pyrrolidinyl, cyclopentanol, or cyclopentanyl.

[0014] In one embodiment of the present invention, R2 is preferably: methylamino, ethylamino, hydroxyl, methoxy, difluoroethylamino, hydrazine-NH-NH2,

[0015] In one embodiment of the present invention, R3, R3' are preferably selected from:

[0016] In one embodiment of the present invention, R4 and R4' are preferably C1-C8 alkyl.

[0017] In one embodiment of the present invention, when R3 and R3' are When, R4 is methyl;

[0018] When R3 and R3' are When R4' is a C1-C8 alkyl group, a primary or secondary amino group substituted with a C1-C8 alkyl group, or a C3-C6 cycloalkyl group.

[0019] In one embodiment of the present invention, the pteridine 7(8H)-one derivatives can be selected from the specific compounds in Table 1 below:

[0020] Table 1

[0021]

[0022]

[0023] In one embodiment of the present invention, the pharmaceutically acceptable salts include potassium salt, sodium salt, hydrochloride, formate, trifluoroacetate, phosphate and sulfate, etc.

[0024] The second object of the present invention is to provide a composition containing the above-mentioned pteridine 7(8H)-one derivative or its stereoisomer or a pharmaceutically acceptable salt thereof.

[0025] In one embodiment of the present invention, the composition contains the above-mentioned pteridine 7(8H)-one derivative or its stereoisomer or its pharmaceutically acceptable salt, and a pharmaceutically acceptable excipient.

[0026] In one embodiment of the present invention, the pharmaceutically acceptable carrier refers to conventional pharmaceutical excipients in the pharmaceutical field, such as diluents, excipients, fillers, binders, wetting agents, absorption enhancers, water, etc., fillers such as starch, sucrose, lactose, microcrystalline cellulose, etc.; binders such as cellulose derivatives, alginates, gelatin and polyvinyl pyrrolidone; wetting agents such as glycerol; disintegrants such as sodium carboxymethyl starch, hydroxypropyl cellulose, agar, calcium carbonate and sodium bicarbonate; absorption enhancers such as quaternary ammonium compounds; surfactants such as cetyl alcohol and sodium lauryl sulfate.

[0027] In one embodiment of the present invention, the composition comprises the above-mentioned pteridine derivative or its stereoisomer or pharmaceutically acceptable salt and at least one pharmaceutically acceptable excipient or carrier.

[0028] In one embodiment of the present invention, the preparation of the above-mentioned pteridine 7(8H)-one derivative or its stereoisomer or its pharmaceutically acceptable salt is carried out by the following reaction formula:

[0029]

[0030] Wherein, in the above reaction formula, R1 and R1', R2, R3 and R3', R4 and R4' are the same as defined above; and R is a C1-C8 alkane.

[0031] The third object of the present invention is to provide the use of the above-mentioned pteridine 7(8H)-one derivatives or their stereoisomers or their pharmaceutically acceptable salts in the preparation of CDK2 inhibitors.

[0032] The fourth object of the present invention is to provide the use of the above-mentioned pteridine 7(8H)-one derivatives or their stereoisomers or their pharmaceutically acceptable salts in the preparation of drugs for preventing or treating cancer.

[0033] In one embodiment of the present invention, the cancer is selected from breast cancer, colon cancer, rectal cancer, kidney cancer, epidermal cancer, liver cancer, lung cancer, esophageal cancer, gallbladder cancer, ovarian cancer, pancreatic cancer, gastric cancer, cervical cancer, thyroid cancer, nasal cancer, head and neck cancer, prostate cancer, skin cancer, myeloid hematopoietic cell tumor, thyroid follicular cancer, tumors originating from mesenchymal cells, central or peripheral nervous system tumors, melanoma, glioma, seminoma, teratoma, osteosarcoma, xeroderma pigmentosum, keratoacanthoma, thyroid follicular cancer or Kaposi's sarcoma.

[0034] Beneficial effects:

[0035] The pteridine derivatives, stereoisomers, or pharmaceutically acceptable salts thereof of the present invention exhibit excellent CDK2 inhibitory activity and can be used as highly effective CDK2 inhibitors. The compounds claimed in the present invention have strong efficacy and selectivity for CDK2, which is beneficial in the development of drugs suitable for use as CDK2 inhibitors and has very broad application prospects. DETAILED DESCRIPTION

[0036] "Alkyl" as used herein refers to a straight or branched saturated hydrocarbon group. In some embodiments, an alkyl group may have 1 to 10 carbon atoms (e.g., 1 to 8 carbon atoms). Examples of alkyl groups include methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, sec-butyl, tert-butyl), pentyl groups (e.g., n-pentyl, isopentyl, neopentyl), hexyl (e.g., n-hexyl and its isomers), etc. Lower alkyl groups generally have up to 4 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl (e.g., n-propyl and isopropyl) and butyl groups (e.g., n-butyl, isobutyl, sec-butyl, tert-butyl). In one embodiment, an alkyl group or two or more alkyl groups may form a bridged alkyl group. That is, wherein the alkyl group is connected through another group (particularly shown in cyclic groups), is bridged by an alkyl chain to form a ring, i.e., a bridged fused ring.

[0037] " Cycloalkyl " of the present invention refers to non-aromatic carbocyclic groups, including cyclic alkyl, alkenyl and alkynyl groups. Cycloalkyl groups can be monocyclic (such as cyclohexyl) or polycyclic (such as, comprising fused, bridged and / or spirocyclic ring systems), wherein carbon atoms are located inside or outside the ring system. Cycloalkyl groups as a whole can have 3 to 14 ring atoms (such as, 3 to 8 carbon atoms for monocyclic cycloalkyl groups and 7 to 14 carbon atoms for polycyclic cycloalkyl groups). Any suitable ring position of the cycloalkyl group can be covalently linked to the defined chemical structure. The example of cycloalkyl groups includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, bornyl, norpinyl, norcaryl, adamantyl and spiro [4.5] decyl, and its homologues, isomers etc.

[0038] The compounds of formula (I) and formula (II) of the present invention also include all pharmaceutically acceptable isotope-labeled compounds, in which one or more atoms are replaced by atoms with the same atomic number, but the atomic mass or mass number is different from the atomic mass or mass number usually found in nature. Isotopes suitable for inclusion in the compounds of formula (I) and formula (II) of the present invention include isotopes of hydrogen, for example 2 H and 3 H, isotopes of carbon, e.g. 11 C. 13 C and 14 C, isotopes of nitrogen, e.g. 13 N and 15 N, isotopes of oxygen, e.g. 15 O. 17 O and 18 O.

[0039] Using heavier isotopes such as deuterium 2 H substitutions may offer certain therapeutic advantages such as greater metabolic stability, eg, increased in vivo half-life or reduced dosage requirements, and are therefore preferred in some circumstances.

[0040] The synthesis methods of the compounds of the present invention will be described in detail below through examples.

[0041] Preparation of intermediate A-0

[0042]

[0043] 2,4-Dichloro-5-nitropyrimidine (30 g, 154.7 mmol) was dissolved in a mixture of DCM and MeOH (300 mL, 1:1 volume ratio). Iron powder (52 g, 928.6 mmol) and NH4Cl (49.7 g, 929.1 mmol) were added portionwise. The temperature was raised to 50°C and the reaction was stirred for 2 h. The reaction was monitored for completion by TLC. The mixture was filtered through Celite while hot and cooled to room temperature. The pH of the reaction mixture was adjusted to 9 with saturated NaHCO3 solution. Water (150 mL) was then added and extracted three times with DCM (150 mL). The organic phases were combined, washed with saturated NaCl solution, dried over Na2SO4, and filtered. The filtrate was concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (eluent: DCM:MeOH = 100:1 (v / v)) to afford A-0 (21 g, 83.6%) as a pale yellow solid. MS-ESI (m / z): 163.983[M+H]+; 1H NMR (400MHz, DMSO-d6) δ8.14 (s, 1H), 6.12 (s, 2H).

[0044] Preparation of intermediate A-1

[0045]

[0046] A-0 (20 g, 122.7 mmol) was dissolved in anhydrous THF (200 mL). A mixed solution of TEA (31.0 g, 306.7 mmol) and cyclopentylamine (26.1 g, 306.7 mmol) was added dropwise at room temperature using a constant pressure bottom funnel. The mixture was stirred at reflux at 60°C for 4 h. TLC confirmed the completion of the reaction. The mixture was cooled to room temperature and concentrated under reduced pressure to remove most of the solvent. Water (100 mL) was then added and extracted three times with EA (150 mL). The organic phases were combined, washed with saturated aqueous NaCl solution, dried over Na2SO4, and filtered. The filtrate was concentrated under reduced pressure to obtain A-1 (23 g, 88.4% yield) as a pale yellow solid. MS-ESI (m / z): 213.114 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ7.35(s,1H),6.66(d,J=6.8Hz,1H),4.95(s,2H),4.23(q,J=6.8Hz,1H),1.9 5(dt,J=12.6,6.4Hz,2H),1.68(tq,J=10.5,3.8,3.3Hz,2H),1.60–1.52(m,2H),1.50–1.42(m,2H).

[0047] Preparation of intermediate A-2

[0048]

[0049] The preparation method of intermediate A-2 refers to A-1, except that cyclopentylamine is replaced by butylamine to obtain a light yellow solid (11.3 g, yield 92.1%). MS-ESI (m / z): 201.099 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ7.35 (s, 1H), 6.54 (d, J = 7.7Hz, 1H), 4.94 (s, 2H), 3.99 (p ,J=6.8Hz,1H),1.56–1.48(m,2H),1.13(d,J=6.5Hz,3H),0.87(t,J=7.4Hz,3H).

[0050] Preparation of intermediate A-3

[0051]

[0052] The preparation method of intermediate A-3 refers to A-1, except that cyclopentylamine is replaced by pentylamine to obtain a light yellow solid (11.6 g, yield 88.2%). MS-ESI (m / z): 215.116 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ7.35(s,1H),6.43(d,J=8.2Hz,1H),4.94(s,2H),3.91(dt,J=7 .8,5.3Hz,1H),1.61–1.53(m,2H),1.46(dt,J=13.6,7.4Hz,2H),0.85(t,J=7.4Hz,6H).

[0053] Preparation of intermediate A-4

[0054]

[0055] The preparation method of intermediate A-4 is similar to that of A-1, except that cyclopentylamine is replaced with tetrahydro-2H-pyran-4-amine to obtain a light yellow solid (11.9 g, yield 85.2%). MS-ESI (m / z): 229.095 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ7.39 (s, 1H), 6.68 (d, J = 7.2Hz, 1H), 4.96 (s, 2H), 4.05–4.01 (m, 1H), 3. 90–3.85(m,2H),3.43(dd,J=11.7,2.1Hz,2H),1.89–1.84(m,2H),1.48(td,J=11.8,7.7Hz,2H).

[0056] Preparation of intermediate A-5

[0057]

[0058] The preparation method of intermediate A-5 refers to A-1, except that cyclopentylamine is replaced with tert-butyl 3-aminopyrrolidine-1-carboxylate to obtain a light yellow solid (12.7 g, yield 66.5%). MS-ESI (m / z): 314.154 [M+H] + ; 1 H NMR(400MHz, DMSO-d6)δ7.42(s,1H),6.89(d,J=6.1Hz,1H),5.02(s,2H),4.48–4.38(m,1H),3.62–3.56(m,1H) ,3.44–3.34(m,2H),3.18–3.12(m,1H),2.18–2.12(m,1H),1.86(dt,J=12.9,6.4Hz,1H),1.41(d,J=3.4Hz,9H).

[0059] Preparation of intermediate A-6

[0060]

[0061] The preparation method of intermediate A-6 refers to A-1, except that cyclopentylamine is replaced with (1R,2R)-2-aminocyclopentane-1-ol to obtain a light yellow solid (10.5 g, yield 81.8%). MS-ESI (m / z): 229.095 [M+H] + ; 1 H NMR(400MHz, DMSO-d6)δ7.37(s,1H),6.65(d,J=6.7Hz,1H),4.97(s,2H),4.82(d,J=4.3Hz,1H),4.06–4.00(m,1H), 3.95(d,J=5.3Hz,1H),2.12–2.05(m,1H),1.87(ddd,J=12.8,6.3,2.2Hz,1H),1.71–1.61(m,2H),1.53–1.37(m,2H).

[0062] Preparation of intermediate A-7

[0063]

[0064] Under nitrogen protection, A-1 (15 g, 70.1 mmol) and K2CO3 (19.5 g, 141.5 mmol) were dissolved in acetone (150 mL). Oxalyl chloride monoethyl ester was slowly added dropwise under ice bath conditions, controlling the temperature not to exceed 5°C. After the addition, the mixture was moved to room temperature for 2 hours. TLC monitored the completion of the reaction, the reaction solution was filtered, the filter cake was washed with acetone (50 mL), and the filtrate was concentrated under reduced pressure to obtain a brown oily liquid. The brown oil was dissolved in EtOH (100 mL) and transferred to a sealed tube. TEA (8.5 g, 84.1 mmol) was added and the temperature was raised to 100°C for 4 hours. TLC monitored the completion of the reaction, cooled to room temperature, and solid precipitated. It was filtered and the filter cake was dried to obtain a white solid A-7 (14.7 g, yield 78.9%). MS-ESI (m / z): 267.090 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ12.30(s,1H),8.29(s,1H),5.48(ddd,J=9.6,7.5,1.9Hz,1H),2.13–2.0 5(m,2H),1.98(td,J=6.0,5.6,3.1Hz,2H),1.83(td,J=8.1,7.3,2.5Hz,2H),1.65–1.57(m,2H).

[0065] Preparation of intermediate A-8

[0066]

[0067] The preparation method of intermediate A-8 refers to A-7, except that A-1 is replaced by A-2 to obtain a white solid (9.4 g, yield 73.7%). MS-ESI (m / z): 255.076 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ12.33(s,1H),8.29(s,1H),5.10(q,J=7.2Hz,1H),2.11–2.0 4(m,1H),1.88(dt,J=14.0,7.1Hz,1H),1.46(d,J=6.9Hz,3H),0.82(t,J=7.5Hz,3H).

[0068] Preparation of intermediate A-9

[0069]

[0070] The preparation method of intermediate A-9 refers to A-7, except that A-1 is replaced by A-3 to obtain a white solid (9.7 g, yield 77.5%). MS-ESI (m / z): 269.098 [M+H]+ ; 1 H NMR (400MHz, DMSO-d6) δ12.39(s,1H),8.31(s,1H),4.95(s,1H),2.11(s,2H),1.90–1.79(m,2H),0.79(t,J=7.5Hz,6H).

[0071] Preparation of intermediate A-10

[0072]

[0073] The preparation method of intermediate A-10 refers to A-7, except that A-1 is replaced by A-4 to obtain a white solid (9.6 g, yield 77.6%). MS-ESI (m / z): 283.068 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ8.25 (s, 1H), 5.21 (td, J=8.0, 4.0Hz, 1H), 3.98 (dd, J= 11.5, 4.5Hz, 2H), 3.45–3.39 (m, 2H), 2.66 (d, J = 7.1Hz, 2H), 1.59–1.55 (m, 2H).

[0074] Preparation of intermediate A-11

[0075]

[0076] The preparation method of intermediate A-11 refers to A-7, except that A-1 is replaced by A-5 to obtain a white solid (9.3 g, yield 79.3%). MS-ESI (m / z): 368.059 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ12.27(s,1H),8.30(s,1H),3.75–3.42(m,4H),3.38(t,J=8. 6Hz, 1H), 2.42 (d, J = 9.6Hz, 1H), 2.18 (dd, J = 8.2, 5.2Hz, 1H), 1.41 (d, J = 11.0Hz, 9H).

[0077] Preparation of intermediate A-12

[0078]

[0079] A-6 (8 g, 35.1 mmol) was dissolved in DCM (80 mL), and imidazole (6 g, 87.75 mmol) and DMAP (0.5 g, 4.1 mmol) were added under nitrogen. The temperature was lowered to 0°C, and tert-butyldiphenylsilyl chloride (10.6 g, 38.6 mmol) was added dropwise. After completion of the addition, the mixture was warmed to room temperature and stirred for 4 h. TLC monitored the reaction for completion. Water was added to the reaction solution, and the mixture was extracted three times with DCM. The organic phases were combined, washed with saturated aqueous NaCl, dried over Na₂SO₄, and filtered. The filtrate was concentrated under reduced pressure to obtain the crude product, which was isolated and purified by silica gel column chromatography (eluent: DCM:MeOH = 150:1 (v / v)) to afford A-12 (9.5 g, 58.1% yield) as a dark brown solid. MS-ESI (m / z): 467.223 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ7.62–7.59(m,4H),7.43–7.32(m,7H),6.55(d,J=7.7Hz,1H),4.86(s,2H),4.49–4.44(m,1H) ,4.15(d,J=4.5Hz,1H),2.12(dt,J=8.9,4.5Hz,1H),1.74(s,1H),1.67–1.59(m,2H),1.52–1.46(m,2H),0.99(s,9H).

[0080] Preparation of intermediate A-13

[0081]

[0082] The preparation method of intermediate A-13 refers to A-7, except that A-1 is replaced by A-12 to obtain a light yellow solid (5.6 g, yield 62.7%). MS-ESI (m / z): 521.176 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ8.17(s,1H),7.43–7.37(m,4H),7.32–7.23(m,5H),7.12(s,1H),5.45–5.40(m,1H),4 .86(s,1H),2.08–2.04(m,1H),1.91(d,J=7.4Hz,2H),1.87–1.83(m,1H),1.77(d,J=5.6Hz,2H),0.92(s,9H).

[0083] Preparation of intermediate A-14

[0084]

[0085] The preparation method of intermediate A-14 is similar to that of I-2, except that A-13 is used as the starting material and 1-methylsulfonyl-4-aminopiperidine is substituted for 4-methylsulfonylaniline to obtain a white solid (0.8 g, yield 62.8%). MS-ESI (m / z): 663.308 [M+H] + ; 1 HNMR(400MHz,DMSO-d6)δ11.71(s,1H),7.97(s,1H),7.41(dd,J=7.3,5.8H z,3H),7.33–7.25(m,5H),7.15(d,J=7.6Hz,2H),5.52(s,1H),4.87(s,1H), 3.67(s,1H),3.52(d,J=12.1Hz,2H),2.88(s,3H),2.88–2.71(m,3H),2.09 –1.96(m,2H),1.84(d,J=44.0Hz,6H),1.52(d,J=11.8Hz,2H),0.91(s,9H).

[0086] Preparation of intermediate A-15

[0087]

[0088] A-2 (5 g, 18.8 mmol) and POCl3 (20 mL) were added sequentially to the reaction flask and refluxed for 4 h. The reaction was monitored by TLC for completion. After cooling to room temperature and concentrating under reduced pressure to remove most of the solvent, the remaining reaction solution was slowly added dropwise to ice water. Solid precipitated and was filtered. The filter cake was dried to obtain A-15 (4.2 g, 78.4% yield) as a white solid. MS-ESI (m / z): 285.044 [M+H] + ; 1 HNMR (400MHz, CDCl3) δ8.95 (s, 1H), 5.84 (ddd, J = 9.6, 7.6, 1.9Hz, 1H), 2.27–2.21 (m, 2H), 2.19–2.11 (m, 2H), 2.05–1.98 (m, 2H), 1.78–1.71 (m, 2H).

[0089] Preparation of intermediate A-16

[0090]

[0091] A-15 (2 g, 7 mmol) was dissolved in EtOH (20 mL), and 1-methylsulfonyl-4-aminopiperidine (1.2 g, 7 mmol) was added. The mixture was heated to 40°C and stirred for 2 h. The reaction was monitored by TLC. The reaction solution was cooled to room temperature, and solid precipitated. The solid was filtered and the filter cake was dried to obtain A-16 (1.8 g, 60.1% yield) as a white solid. MS-ESI (m / z): 427.146 [M+H] + ; 1 H NMR (400MHz, CDCl3) δ8.64(s,1H),6.53(d,J=7.9Hz,1H),5.81(t,J=8.4Hz,1H),4.17–4.11(m,1H),3.83(d,J=12.4Hz,2H),2.9 9(dd,J=12.6,10.0Hz,2H),2.85(s,3H),2.23(dd,J=13.2,4.3Hz,4H),2.16–2.11(m,2H),2.03–1.97(m,2H),1.77–1.71(m,4H).

[0092] Preparation of intermediate A-17

[0093]

[0094] Compound A-17 was prepared by referring to A-16, except that 1-methylsulfonyl 4-aminopiperidine was replaced with 4-amino-N,N-dimethylpiperidine-1-sulfonamide to obtain a white solid (1.6 g, yield 51.1%). MS-ESI (m / z): 456.180 [M+H] + ; 1 HNMR(400MHz, CDCl3)δ8.60(s,1H),6.47(s,1H),5.75(s,1H),4.08(s,1H),3.70(s,2H) ,3.06(d,J=20.0Hz,2H),2.82(s,6H),2.10(s,4H),1.95(s,2H),1.64(d,J=23.8Hz,4H).

[0095] Example 1 8-Cyclopentyl-2-((4-(methylsulfonyl)phenyl)amino)-5,8-dihydropterin-6,7-dione (I-1)

[0096]

[0097] A-2 (1 g, 3.8 mmol) was dissolved in n-butanol (10 mL), and 4-methylsulfonaniline (0.7 g, 4.2 mmol) and p-toluenesulfonic acid monohydrate (0.7 g, 3.8 mmol) were added sequentially. The temperature was raised to 120°C and the mixture was stirred under reflux for 12 h. The reaction was monitored for completion by TLC. The reaction solution was cooled to room temperature and filtered to obtain a yellow solid. PE slurry was then used to obtain compound I-1 (0.7 g, 45.9% yield) as a pale yellow solid. MS-ESI (m / z): 402.142 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ10.11(s,1H),8.24(s,1H),7.94(d,J=8.9Hz,2H),7.83–7.80(m,2H),5.65(d,J=8.7Hz,1H),3. 34(s,1H),3.15(s,3H),2.17(dd,J=12.5,7.5Hz,2H),1.96(d,J=8.4Hz,2H),1.89–1.82(m,2H),1.63(q,J=6.1Hz,2H).

[0098] Example 2 8-Cyclopentyl-6-hydroxy-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pterin-7(8H)-one (I-2)

[0099]

[0100] A-2 (5 g, 18.8 mmol) was dissolved in DMSO (50 mL), and DIPEA (2.9 g, 22.6 mmol) and 1-methylsulfonyl-4-aminopiperidine (4.7 g, 26.3 mmol) were added sequentially. The reaction was heated to 100°C for 6 h, then to 110°C for another 6 h. The reaction was monitored for completion by TLC. The mixture was cooled to room temperature, added with water, and extracted three times with DCM. The organic phases were combined, washed with saturated aqueous NaCl, dried over Na2SO4, and filtered. The filtrate was decompressed to obtain the crude product, which was isolated and purified by silica gel column chromatography (eluent: DCM:MeOH = 100:1 (v / v)) to afford compound I-2 as a white solid (4.2 g, 54.7% yield). MS-ESI (m / z): 409.150 [M+H]. + ; 1H NMR (400MHz, DMSO-d6) δ11.74(s,1H),8.03(s,1H),7.13(d,J=7.4Hz,1H),5.60(t,J=8.7Hz,1H),3.80(s,1H),3.54(dt,J=12.7,4.2Hz,2H) ,2.88(s,3H),2.84(dd,J=11.5,2.7Hz,2H),2.18(t,J=7.3Hz,2H),1.98–1.92(m,4H),1.77(d,J=9.3Hz,2H),1.57(dd,J=17.2,8.0Hz,4H).

[0101] Example 3 8-Cyclopentyl-2-((1-(ethylsulfonyl)piperidin-4-yl)amino)-6-hydroxypterin-7(8H)-one (I-3)

[0102]

[0103] The preparation method of compound I-3 refers to compound I-2, except that 1-methylsulfonyl 4-aminopiperidine is replaced with 1-(ethylsulfonyl)piperidin-4-amine hydrochloride to obtain compound I-3 as a white solid (0.76 g, yield 47.4%). MS-ESI (m / z): 423.127 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ11.75(s,1H),8.03(s,1H),7.15(s,1H),5.60(t,J=8.8Hz,1H),3.81(s,1H),3.62–3.56(m,2H),3.05(t, J=7.4Hz,2H),2.97–2.90(m,2H),2.17(d,J=10.3Hz,2H),1.96–1.89(m,4H),1.81–1.74(m,2H),1.60–1.49(m,4H),1.22(s,3H).

[0104] Example 4 8-Cyclopentyl-2-((1-(cyclopropylsulfonyl)piperidin-4-yl)amino)-6-hydroxypterin-7(8H)-one (I-4)

[0105]

[0106] Compound I-4 was prepared by referring to compound I-2, except that 1-methylsulfonyl-4-aminopiperidine was replaced with 1-(cyclopropylsulfonyl)piperidin-4-amine hydrochloride to obtain compound I-4 as a white solid (0.7 g, yield 43.2%). MS-ESI (m / z): 435.206 [M+H] + ;1 H NMR (400MHz, DMSO-d6) δ11.74(s,1H),8.03(s,1H),7.13(s,1H),5.62–5.56(m,1H),3.81(s,1H),3.60(d,J=12.0Hz,2H),2.9 7(d,J=11.8Hz,2H),2.17(d,J=7.9Hz,2H),1.94(s,4H),1.78(s,2H),1.60–1.53(m,4H),1.30(s,2H),0.99(d,J=7.8Hz,2H).

[0107] Example 5 4-((8-cyclopentyl-6-hydroxy-7-oxo-7,8-dihydropterin-2-yl)amino)-N,N-dimethylpiperidine-1-sulfonamide (I-5)

[0108]

[0109] The preparation method of compound I-5 refers to compound I-2, except that 1-methylsulfonyl 4-aminopiperidine is replaced with 4-amino-N,N-dimethylpiperidine-1-sulfonamide hydrochloride to obtain compound I-5 as a pale yellow solid (0.74 g, yield 45.1%). MS-ESI (m / z): 438.191 [M+H] + ; 1 H NMR (400MHz, CDCl3) δ8.22(s,1H),5.65(d,J=8.8Hz,1H),3.91(s,1H),3.69(d,J=12.9Hz,2H),3.02(d,J=10.6 Hz, 2H), 2.85 (s, 6H), 2.26 (d, J = 9.2Hz, 2H), 2.12 (d, J = 10.3Hz, 4H), 1.92–1.88 (m, 2H), 1.69 (d, J = 8.5Hz, 4H).

[0110] Example 6 8-(sec-butyl)-6-hydroxy-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pterin-7(8H)-one (I-6)

[0111]

[0112] The preparation method of compound I-6 refers to compound I-2, except that A-8 is used as the starting material to obtain a light yellow solid compound I-6 (0.8 g, yield 51.3%). MS-ESI (m / z): 397.182 [M+H] + ; 1H NMR (400MHz, DMSO-d6) δ11.81(s,1H),8.05(s,1H),7.17(s,1H),5.22(s,1H),3.77(s,1H),3.54(dd,J=11.9,3.7Hz,2H ), 2.88 (s, 3H), 2.88–2.82 (m, 2H), 2.26–2.05 (m, 2H), 2.00–1.77 (m, 4H), 1.55 (t, J = 11.0Hz, 2H), 1.46 (d, J = 6.8Hz, 4H).

[0113] Example 7 6-Hydroxy-2-((1-(methylsulfonyl)piperidin-4-yl)amino)-8-(pentan-3-yl)pterin-7(8H)-one (I-7)

[0114]

[0115] The preparation method of compound I-7 is similar to that of I-2, except that A-9 is used as the starting material to obtain a pale yellow solid compound I-7 (1 g, yield 52.2%). MS-ESI (m / z): 411.203 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ11.87(s,1H),8.06(s,1H),7.18(s,1H),5.19(s,1H),3.74(s ,1H),3.54(d,J=11.8Hz,2H),2.88(s,5H),2.18–1.80(m,6H),1.55(d,J=11.3Hz,2H).

[0116] Example 8 6-Hydroxy-2-((1-(methylsulfonyl)piperidin-4-yl)amino)-8-(tetrahydro-2H-pyran-4-yl)pterin-7(8H)-one (I-8)

[0117]

[0118] The preparation method of compound I-8 refers to I-2, except that A-10 is used as the starting material to obtain a light yellow solid compound I-8 (0.9 g, yield 48.3%). MS-ESI (m / z): 425.217 [M+H] + ; 1H NMR (400MHz, DMSO-d6) δ10.80(s,1H),8.05(s,1H),7.18(s,1H),5.29(q,J=10.4,9.3Hz,1H),3.99(dd,J=11.5,4.5Hz,2H),3.76(s,1H),3.56( dd,J=10.1,6.1Hz,2H),3.42–3.36(m,2H),2.88(s,3H),2.87–2.82(m,2 H), 2.74 (dt, J = 13.6, 6.8 Hz, 2H), 2.02–1.95 (m, 2H), 1.58–1.50 (m, 4H).

[0119] Example 9 6-Hydroxy-2-((1-(methylsulfonyl)piperidin-4-yl)amino)-8-(pyrrolidin-3-yl)pterin-7(8H)-monohydrochloride (I-9)

[0120]

[0121] A-10 (1 g, 2.7 mmol) was dissolved in DMSO (10 mL), and DIPEA (0.4 g, 3.3 mmol) and 1-methylsulfonyl-4-aminopiperidine (0.7 g, 3.8 mmol) were added sequentially. The reaction was heated to 100°C for 6 h, then to 110°C for another 6 h. The reaction was monitored for completion by TLC. The mixture was cooled to room temperature, added with water, and extracted three times with DCM. The organic phases were combined, washed with saturated aqueous NaCl, dried over Na₂SO₄, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent: DCM:MeOH = 50:1 (v / v)) to obtain the intermediate. The intermediate was dissolved in HCl-MeOH (5 mL) and stirred at room temperature overnight. The reaction was monitored for completion by TLC. The solvent was removed by concentration under reduced pressure to obtain compound I-9 (0.4 g, 33.3% yield) as a white solid. MS-ESI (m / z): 410.179 [M+H] + ; 1 HNMR(400MHz,Deuterium Oxide)δ7.98(s,1H),6.04–5.99(m,1H),3.88(d,J=12.0Hz,1H),3.55–3.47(m,4H),3.29–3.20(m,2H),2. 92–2.86(m,2H),2.83(s,3H),2.44(dh,J=13.5,4.2Hz,2H),2.19(s,2H),1.97(s,1H),1.62–1.55(m,2H).

[0122] Example 10 6-Hydroxy-8-((1R,2R)-2-hydroxycyclopentyl)-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pterin-7(8H)-one (I-10)

[0123]

[0124] A-14 (0.5 g, 0.8 mmol) was dissolved in THF (5 mL), and tetramethylammonium fluoride (0.2 g, 2 mmol) was added. The mixture was stirred at room temperature overnight. The reaction was monitored for completion by TLC. The reaction solution was concentrated under reduced pressure to remove most of the solvent. Water was added and the mixture was extracted three times with DCM. The organic phases were combined, washed with saturated aqueous NaCl, dried over Na2SO4, and filtered. The filtrate was decompressed to obtain the crude product, which was isolated and purified by silica gel column chromatography [eluent: DCM:MeOH = 100:1 (v / v)] to afford compound I-10 (0.22 g, 62.5% yield) as a white solid. MS-ESI (m / z): 425.173 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ11.75(s,1H),8.06(s,1H),7.15(s,1H),5.35–5.28( m,1H),4.79(s,1H),4.76(d,J=7.0Hz,1H),3.78(s,1H),3.58–3.53(m,2H),2. 89(s,3H),2.83(dt,J=11.9,3.2Hz,2H),2.15–2.02(m,2H),1.99–1.93(m,2H ), 1.84 (p, J = 5.1, 4.4Hz, 2H), 1.73 (s, 1H), 1.55 (dq, J = 18.2, 7.2, 6.3Hz, 3H).

[0125] Example 11 8-Cyclopentyl-6-(methylamino)-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pterin-7(8H)-one (II-11)

[0126]

[0127] I-2 (0.5 g, 1.2 mmol) and POCl₃ (5 mL) were added sequentially to a reaction flask and refluxed for 4 h. The reaction was monitored for completion by TLC. The mixture was cooled to room temperature and concentrated under reduced pressure to remove most of the solvent. The remaining reaction solution was then slowly added dropwise to ice water, resulting in a solid precipitate. This was filtered to obtain a filter cake. The filter cake and 30% methylamine alcohol solution (3 mL) were added to the reaction flask and refluxed for 6 h. The reaction was monitored for completion by TLC. The mixture was cooled to room temperature, and water (10 mL) was added to the reaction solution. The mixture was extracted three times with DCM (15 mL). The organic phases were combined, washed with saturated aqueous NaCl, dried over Na₂SO₄, and filtered. The filtrate was decompressed to obtain the crude product, which was purified by silica gel column chromatography (eluent: DCM:MeOH = 200:1 (v / v)) to afford compound II-11 as a yellow solid (0.34 g, 65.9% yield). MS-ESI (m / z): 422.143 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ8.34(d,J=1.0Hz,1H),7.42(d,J=5.1Hz,1H),7.11(d,J=7.8Hz,1H),5.74(t,J=8.7Hz,1H),3.84(s,1H),3.55(d,J=11. 9Hz, 2H), 2.88 (d, J = 0.9Hz, 3H), 2.85 (dd, J = 11.4, 3.6Hz, 5H), 2.22 (s, 2H), 1.97 (d, J = 11.5Hz, 4H), 1.81 (d, J = 10.3Hz, 2H), 1.65–1.54 (m, 4H).

[0128] Example 12 8-Cyclopentyl-2-((1-(ethylsulfonyl)piperidin-4-yl)amino)-6-(methylamino)pterin-7(8H)-one (II-12)

[0129]

[0130] The preparation of compound II-12 was based on compound II-11, except that I-3 was used as the starting material to obtain yellow solid compound II-12 (0.09 g, yield 29.2%). MS-ESI (m / z): 436.239 [M+H] + ; 1H NMR(400MHz, CDCl3)δ8.48(s,1H),6.21(d,J=5.5Hz,1H),5.79–5.73(m,1H),5.13(s,1H),4.05–3.97(m,1H),3.80(dd,J=12.5,4.5Hz,2H),3.07( d,J=5.0Hz,3H),3.06–2.98(m,4H),2.34(t,J=9.6Hz,2H),2.21–2.15(m, 2H), 2.05 (s, 2H), 1.91 (t, J = 4.9Hz, 2H), 1.73–1.65 (m, 4H), 1.27 (s, 3H).

[0131] Example 13 8-Cyclopentyl-2-((1-(cyclopropylsulfonyl)piperidin-4-yl)amino)-6-(methylamino)pterin-7(8H)-one (II-13)

[0132]

[0133] The preparation method of compound II-13 refers to II-11, except that I-4 is used as the starting material to obtain yellow solid compound II-13 (0.1 g, yield 32.4%). MS-ESI (m / z): 448.235 [M+H] + ; 1 H NMR(400MHz, CDCl3)δ8.48(s,1H),6.21(d,J=5.3Hz,1H),5.79–5.74(m,1H),4.00(d,J=8.1Hz,1H),3.82–3.77(m,2H),3.12–3.06(m,5H) ,2.19(dd,J=13.1,3.8Hz,2H),2.10–2.01(m,4H),1.93–1.89(m,2H),1.71(dt,J=6.9,2.8Hz,4H),1.23–1.21(m,2H),1.04–1.02(m,2H).

[0134] Example 14 8-Cyclopentyl-6-(ethylamino)-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pterin-7(8H)-one (II-14)

[0135]

[0136] The preparation method of compound II-14 refers to compound II-11, except that methylamino alcohol solution is replaced with ethylamino alcohol solution to obtain yellow solid compound II-14 (0.32 g, yield 60.3%). MS-ESI (m / z): 436.234 [M+H] + ;1 H NMR (400MHz, DMSO-d6) δ8.33(s,1H),7.36(t,J=5.9Hz,1H),5.75(dd,J=10.5,7.0Hz,1H),3.55(d,J=12.0Hz,2H),3.37–3.30(m,4H),2.88 (s,3H),2.86(d,J=2.7Hz,1H),2.25–2.17(m,2H),1.97(d,J=11.9Hz,4H),1.81(t,J=4.8Hz,2H),1.64–1.53(m,4H),1.15(t,J=7.1Hz,3H).

[0137] Example 15 8-Cyclopentyl-6-((2,2-difluoroethyl)amino)-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pterin-7(8H)-one (II-15)

[0138]

[0139] Compound II-15 and its preparation method refer to compound II-11, except that the methylamine alcohol solution is replaced with difluoroethylamine solution to obtain white solid compound II-15 (0.19 g, yield 55.4%). MS-ESI (m / z): 472.200 [M+H] + ; 1 H NMR (400MHz, CDCl3) δ8.45(s,1H),6.36(t,J=6.5Hz,1H),5.76(d,J=8.9Hz,1H),5.06(d,J=7.8Hz,1H),4.02–3.96(m,1H),3.93–3.85(m,2H),3.80(d ,J=12.3Hz,2H),3.00–2.94(m,2H),2.85(s,3H),2.36–2.30(m,2H),2.23– 2.18(m,2H),2.07(t,J=8.0Hz,2H),1.96–1.90(m,2H),1.75–1.67(m,4H).

[0140] Example 16 4-((8-cyclopentyl-6-((2,2-difluoroethyl)amino)-7-oxo-7,8-dihydropterin-2-yl)amino)-N,N-dimethylpiperidine-1-sulfonamide (II-16)

[0141]

[0142] The preparation method of compound II-16 refers to II-11, except that I-5 is used as the starting material and the methylamine alcohol solution is replaced with difluoroethylamine solution to obtain a pale yellow solid compound II-16 (0.08 g, yield 23.3%). MS-ESI (m / z): 501.224 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ8.36(s,1H),7.67(d,J=6.2Hz,1H),6.19(d,J=4.3Hz,1H),5.74(t,J=9.0Hz,1H),3.86(s,1H),3.72(p,J=4.5Hz,2H ), 3.58 (d, J = 12.5Hz, 2H), 2.97 (t, J = 11.9Hz, 2H), 2.76 (s, 6H), 2.24 (s, 2H), 1.96 (d, J = 15.9Hz, 4H), 1.84–1.78 (m, 2H), 1.66–1.53 (m, 4H).

[0143] Example 17 8-Cyclopentyl-6-methoxy-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pterin-7(8H)-one (II-17)

[0144]

[0145] I-2 (0.5 g, 1.2 mmol) and POCl3 (5 mL) were added to the reaction flask sequentially and refluxed for 4 h. The reaction was monitored for completion by TLC. The mixture was cooled to room temperature and concentrated under reduced pressure to remove most of the solvent. The remaining reaction solution was slowly added dropwise to ice water, where solid precipitated. The filter cake was filtered to obtain a filter cake. The filter cake and DMF-DMA (8 mL) were added to the reaction flask, and the temperature was raised to 120°C for 4 h. The reaction was monitored for completion by TLC. The mixture was cooled to room temperature and added dropwise to ice water, where solid precipitated. The solid was filtered and dried to obtain compound II-17 as a white solid (0.29 g, 56.1% yield). MS-ESI (m / z): 423.171 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ8.47(s,1H),8.34(s,1H),5.70(s,1H),3.89(s,3H),3.57(d,J=3.4Hz,2H),3.54(s,2H ),2.88(d,J=1.6Hz,3H),2.83(s,1H),2.22(s,2H),1.97(d,J=10.8Hz,4H),1.79(s,2H),1.61(d,J=9.5Hz,4H).

[0146] Example 18 8-(sec-butyl)-6-methoxy-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pterin-7(8H)-one (II-18)

[0147]

[0148] The preparation method of compound II-18 refers to II-17, except that I-3 is used as the starting material to obtain a light yellow solid compound II-18 (0.28 g, yield 54.6%). MS-ESI (m / z): 411.198 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ8.47(s,1H),7.56(s,1H),5.33(s,1H),3.90(s,3H),3.84(s,1 H),3.59–3.53(m,2H),2.89(s,5H),2.14–1.87(m,4H),1.61–1.54(m,2H),1.50(s,3H).

[0149] Example 19 6-Methoxy-2-((1-(methylsulfonyl)piperidin-4-yl)amino)-8-(pentan-3-yl)pterin-7(8H)-one (II-19)

[0150]

[0151] The preparation method of compound II-19 refers to II-17, except that I-4 is used as the starting material to obtain a light yellow solid compound II-19 (0.22 g, yield 53.2%). MS-ESI (m / z): 425.179 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ8.49(s,1H),7.64(s,1H),5.33(s,1H),3.91(s,3H),3.56(d,J= 11.6Hz, 2H), 2.90 (s, 5H), 2.34 (s, 2H), 1.90 (d, J = 66.9Hz, 4H), 1.58 (d, J = 11.9Hz, 2H).

[0152] Example 20 6-Methoxy-2-((1-(methylsulfonyl)piperidin-4-yl)amino)-8-(tetrahydro-2H-pyran-4-yl)pterin-7(8H)-one (II-20)

[0153]

[0154] The preparation method of compound II-20 refers to II-17, except that I-5 is used as the starting material to obtain a light yellow solid compound II-20 (0.23 g, yield 55.7%). MS-ESI (m / z): 439.136 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ8.47(s,1H),7.60(d,J=51.5Hz,1H),5.42(s,1H),4.00(dd,J=11.2,4.4Hz,2H),3.89(s,4H),3. 59 (s, 2H), 3.42 (d, J = 12.4Hz, 2H), 2.90 (s, 3H), 2.85 (d, J = 12.3Hz, 4H), 2.01 (d, J = 19.3Hz, 2H), 1.58 (t, J = 13.3Hz, 4H).

[0155] Example 21 8-Cyclopentyl-6-hydrazino-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pterin-7(8H)-one (II-21)

[0156]

[0157] The preparation method of compound II-21 refers to compound II-11, except that the methylamino alcohol solution is replaced with hydrazine hydrate to obtain yellow solid compound II-21 (0.24 g, yield 46.4%). MS-ESI (m / z): 423.214 [M+H] + ; 1 H NMR(400MHz, DMSO-d6)δ8.36(s,1H),7.17(d,J=7.7Hz,1H),5.78–5.71(m,1H),3.85(s,1H),3.55(d,J=12.2Hz,2H),2.8 9(s,3H),2.85(dd,J=11.7,2.7Hz,2H),2.21(s,2H),1.97(dd,J=10.3,5.2Hz,4H),1.84–1.78(m,2H),1.64–1.55(m,4H).

[0158] Example 22 8-Cyclopentyl-6-hydrazino-2-((4-(methylsulfonyl)phenyl)amino)pterin-7(8H)-one (II-22)

[0159]

[0160] The preparation method of compound II-22 refers to compound II-11, except that I-1 is used as the starting material and methylamino alcohol solution is replaced with hydrazine hydrate to obtain yellow solid compound II-22 (0.23 g, yield 46.2%). MS-ESI (m / z): 416.174 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ10.10(s,1H),8.55(s,1H),7.90(dd,J=62.1,8.5Hz,4H),5.78(d,J=18.0 Hz, 1H), 4.53 (s, 1H), 3.36 (s, 2H), 3.16 (s, 3H), 2.23 (s, 2H), 1.95 (d, J = 42.5Hz, 4H), 1.66 (s, 2H).

[0161] Example 23 5-Cyclopentyl-7-((1-(methylsulfonyl)piperidin-4-yl)amino)-[1,2,4]triazolyl[4,3-f]pterin-4(5H)-one (II-23)

[0162]

[0163] II-21 (0.18 g, 0.4 mmol) was dissolved in triethyl orthoformate (2 mL), heated to 80°C, and stirred for 2 h. The reaction was monitored for completion by TLC. After cooling to room temperature, the reaction solution was slowly added dropwise to ice water. Solid precipitated, which was filtered and the filter cake dried to afford compound II-23 as a white solid (0.12 g, 65.2% yield). MS-ESI (m / z): 433.209 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ9.69(s,1H),9.08(s,1H),8.39(s,1H),5.75(s,1H),3.85(s,1H),3.56(d,J=11.9Hz,2H),2.92(d,J=2.7 Hz, 1H), 2.89 (d, J = 3.4Hz, 3H), 2.86 (d, J = 2.7Hz, 1H), 2.25 (s, 2H), 1.98 (d, J = 12.4Hz, 4H), 1.83 (s, 2H), 1.60 (d, J = 11.3Hz, 4H).

[0164] Example 24 5-Cyclopentyl-7-((4-(methylsulfonyl)phenyl)amino)-[1,2,4]triazolo[4,3-f]pterin-4(5H)-one (II-24)

[0165]

[0166] The preparation method of compound II-24 refers to compound II-23, except that II-22 is used as the starting material to obtain yellow solid compound II-24 (0.24 g, yield 46.4%). MS-ESI (m / z): 426.155 [M+H] + ; 1 H NMR(400MHz,DMSO-d6)δ10.48(s,1H),9.78(s,1H),9.31(s,1H),7.99–7.83(m,4H),5.83– 5.75(m,1H),3.18(s,3H),2.27(q,J=6.6Hz,2H),2.06–1.88(m,4H),1.66(q,J=6.1Hz,2H)

[0167] Example 25 8-Cyclopentyl-2-(ethylamino)-6-((1-(methylsulfonyl)piperidin-4-yl)amino)pterin-7(8H)-one (III-25)

[0168]

[0169] A-16 (0.5 g, 1.2 mmol) was dissolved in DMSO (5 mL), and ethylaminoethanol (1 mL) was added. The temperature was raised to 80°C and stirred for 6 h. The reaction was monitored by TLC. The reaction solution was cooled to room temperature and added dropwise to ice water. Solid precipitated and was filtered. The filter cake was dried to obtain compound III-25 as a white solid (0.24 g, yield 45.8%). MS-ESI (m / z): 436.252 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ8.29(s,1H),7.25(d,J=8.2Hz,1H),7.10(s,1H),5.76(t,J=8.7Hz,1H),3.98–3.91(m,1H),3.54(dd,J=9.8,6. 4Hz,2H),3.30(dd,J=7.3,5.9Hz,2H),2.90(d,J=2.8Hz,1H),2.88(s,3H),2.84(d,J=2.6Hz,1H),2.24(s,2H),2.00–1.91(m,4H),1.85–

[0170] 1.78(m,2H),1.71–1.60(m,4H),1.13(t,J=7.1Hz,3H).

[0171] Example 26 8-Cyclopentyl-2-((2,2-difluoroethyl)amino)-6-((1-(methylsulfonyl)piperidin-4-yl)amino)pterin-7(8H)-one (III-26)

[0172]

[0173] The preparation method of compound III-26 refers to compound III-25, except that the ethylamine alcohol solution is replaced with difluoroethylamine to obtain yellow solid compound III-26 (0.24 g, yield 46.4%). MS-ESI (m / z): 472.218 [M+H] + ; 1 H NMR(400MHz, DMSO-d6)δ8.34(s,1H),7.46(t,J=6.2Hz,1H),7.37(d,J=8.3Hz, 1H),5.78–5.72(m,1H),4.01–3.93(m,1H),3.75–3.66(m,2H),3.55(dd,J=9.7 ,6.5Hz,2H),2.92–2.89(m,1H),2.88(s,3H),2.87–2.84(m,1H),2.23(d,J=10 .5Hz,2H),1.96(tt,J=12.2,8.0Hz,4H),1.87–1.80(m,2H),1.73–1.60(m,4H).

[0174] Example 27 8-Cyclopentyl-2-hydrazino-6-((1-(methylsulfonyl)piperidin-4-yl)amino)pterin-7(8H)-one (III-27)

[0175]

[0176] The preparation method of compound III-27 refers to compound III-25, except that the ethylamino alcohol solution is replaced with hydrazine hydrate to obtain yellow solid compound III-27 (0.22 g, yield 43.3%). MS-ESI (m / z): 423.212 [M+H] + ; 1 H NMR (400MHz, DMSO-d6) δ8.34(s,1H),8.14(s,1H),7.31(d,J=8.2Hz,1H),5.84(t,J=8.7Hz,1H),4.41(s,1H),3.99–3.93(m,1H),3.59–3.53(m,2H ),2.90(d,J=2.6Hz,1H),2.88(s,3H),2.84(d,J=2.6Hz,1H),2.21(t,J= 9.9Hz, 2H), 2.02–1.91 (m, 4H), 1.83 (t, J = 5.1Hz, 2H), 1.71–1.60 (m, 4H).

[0177] Example 28 4-((8-cyclopentyl-2-(ethylamino)-7-oxo-7,8-dihydropterin-6-yl)amino)-N,N-dimethylpiperidine-1-sulfonamide (III-28)

[0178]

[0179] The preparation method of compound III-28 refers to compound III-25, except that A-17 is used as the starting material to obtain yellow solid compound III-28 (0.25 g, yield 45.4%). MS-ESI (m / z): 465.258 [M+H] + ; 1 H NMR(400MHz, CDCl3)δ8.43(s,1H),6.07(d,J=7.8Hz,1H),5.85–5.79(m,1H),4.07–4.01(m,1H),3.75–3.69(m,2H),3.51–3.45(m,2H),3.11–3.0 4(m,2H),2.85(s,6H),2.34(dd,J=12.4,7.4Hz,2H),2.15(dd,J=13.1,3.7Hz,2H),2.06(dq,J=7.9,3.5,2.3Hz,2H),1.90(q,J=7.9,6.7Hz,2H).

[0180] Example 29 4-((8-cyclopentyl-2-((2,2-difluoroethyl)amino)-7-oxo-7,8-dihydropterin-6-yl)amino)-N,N-dimethylpiperidine-1-sulfonamide (III-29)

[0181]

[0182] The preparation method of compound III-29 refers to compound III-25, except that A-17 is used as the starting material and difluoroethylamine is used instead of ethylamine solution to obtain compound III-29 as a yellow solid (0.28 g, yield 46.7%). MS-ESI (m / z): 501.245 [M+H] + ; 1H NMR (400MHz, CDCl3) δ8.46(s,1H),6.13(s,1H),5.78(t,J=8.8Hz,1H),4.05(dt,J=7.6,3.7Hz,1H),3.91–3.83(m,2H),3.75–3.70(m,2H),3.11– 3.04(m,2H),2.85(s,6H),2.31(dd,J=12.6,7.5Hz,2H),2.15(dd,J=13. 1,3.7Hz,2H),2.09–2.03(m,2H),1.95–1.88(m,2H),1.74–1.62(m,4H).

[0183] Example 30 4-((8-cyclopentyl-2-hydrazino-7-oxo-7,8-dihydropterin-6-yl)amino)-N,N-dimethylpiperidine-1-sulfonamide (III-30)

[0184]

[0185] The preparation method of compound III-30 refers to compound III-25, except that A-17 is used as the starting material and hydrazine hydrate is used instead of ethylaminoethanol solution to obtain compound III-30 as a yellow solid (0.28 g, yield 51.7%). MS-ESI (m / z): 452.240 [M+H] + ; 1 H NMR (400MHz, CDCl3) δ8.50 (s, 1H), 6.41 (s, 1H), 6.16 (d, J = 7.8Hz, 1H), 5.84 (t,J=8.8Hz,1H),4.09–4.03(m,1H),3.73(dd,J=10.7,6.8Hz,2H),3.10–3. 04(m,2H),2.85(s,6H),2.30(dd,J=12.4,7.5Hz,2H),2.16(dd,J=13.2,3.7 Hz,2H),2.09–2.03(m,2H),1.97–1.90(m,2H),1.64(dt,J=10.7,2.2Hz,4H).

[0186] Example 31 Activity Determination of Compounds

[0187] 1. Evaluation of CDK2 Kinase Inhibitory Activity

[0188] ① Compound Preparation: Dissolve compound powder in 100% DMSO to prepare a 10mM stock solution. Test compound at a concentration of 500nM in duplicate. Dilute the stock solution 100-fold with 100% DMSO in a 384-well plate. Use an Echo 550 dispenser to transfer 250nL of the compound at 100-fold the final concentration to the target plate. Add 250nL of 100% DMSO to each of the negative and positive control wells.

[0189] ② Preparation of kinase: Prepare 1× Kinase buffer and use it to prepare a kinase solution with a final concentration of 2.5 times.

[0190] ③ Add 10 μL of 2.5x final concentration of kinase solution to each of the compound wells and the positive control wells; add 10 μL of 2.5x kinase buffer to the negative control wells. Centrifuge at 1000 rpm for 30 seconds, shake to mix, and incubate at room temperature for 10 minutes.

[0191] ④ Prepare a mixture of ATP and Kinase substrate 22 at a final concentration of 25 / 15 times using 1× Kinase buffer. Add 10 μL to the wells to initiate the reaction. Centrifuge the 384-well plate at 1000 rpm for 30 seconds, shake to mix, and incubate at room temperature for 30 minutes.

[0192] ⑤ Stop the reaction: Add 30 μL of stop assay solution to stop the kinase reaction, centrifuge at 1000 rpm for 30 seconds, oscillate to mix, and read the conversion rate using a microplate reader. Calculation formula: Inhibition rate (%) = ((Conversion rate mean % of positive control wells - Conversion rate mean % of test compound) / (Conversion rate mean % of positive control wells - Conversion rate mean % of negative control wells)) × 100. GraphPad Prism 5 software was used to fit the dose-effect curve, with X-axis = log [concentration] and Y-axis = inhibition rate (%), to calculate the IC value of the compound against CDK2-cyclin E kinase. 50 Value, fitting formula: Y = Bottom + (Top-Bottom) / (1 + 10^((LogIC 50 -X)*HillSlope)).

[0193] 2. Evaluation of HCT 116 and MV4-11 Cell Proliferation Inhibitory Activity

[0194] ①HCT 116 cells: seeding density is 5×10 per ml 4Cell suspension (100 μL) was added to a 96-well plate and cultured in an incubator for 24 h. The culture medium was removed and solutions of the test compound diluted to different concentrations (150 μL) were added. A blank control group (culture medium) and a negative control group (cells and culture medium) were set up at the same time and cultured in an incubator for 48 h. After removing the culture medium, MTT solution (0.5 mg mL -1 , 100 μL), and continue culturing in an incubator for 4 h. Remove the MTT solution and DMSO (100 μL). After shaking the plate, read the absorbance at 570 nM using a microplate reader.

[0195] ②MV4-11 cells: seeding density is 1×10 per ml 5 To a 96-well plate, add the cell suspension (100 μL) diluted to various concentrations of the test compound (150 μL). A blank control and a negative control were also set up. The cells were incubated in an incubator for 72 hours. CCK-8 solution (10 μL) was added and the cells were incubated in an incubator for 4 hours. After shaking the plate, the absorbance was read at 450 nM using a microplate reader.

[0196] GraphPad Prism 5 software was used to calculate the inhibition rate at different concentrations, and the inhibition rate curve was fitted into the corresponding function to calculate the IC 50 Calculation formula: Cell growth inhibition rate (%) = 1-(absorbance value of experimental well-absorbance value of blank well) / (absorbance value of negative control well-absorbance value of blank well) × 100.

[0197] This example discloses the in vitro CDK2 kinase inhibitory activity of the compounds and the anti-tumor cell proliferation activity test results of some compounds with good inhibitory activity, as shown in Table 2 and Table 3:

[0198] Table 2 In vitro CDK2 kinase inhibitory activity test results of different pteridine 7(8H)-ketone compounds

[0199]

[0200] Example 2 exhibited superior CDK2 inhibitory activity compared to Example 1, indicating that the introduction of a piperidinamine at the 2-position of pyrimidine significantly enhanced the compound's activity compared to aniline. Examples 4 and 5 exhibited lower CDK2 kinase inhibition rates than Examples 2 and 3, indicating that the introduction of a cyclopropyl or N,N-dimethyl group into the sulfonyl group was significantly less effective than the introduction of a chain alkyl group. Examples 17-22 exhibited significant CDK2 inhibitory activity, with Examples 17 and 21 showing the highest inhibitory activity, at 82% and 86%, respectively. However, Examples 25-30 exhibited low CDK2 inhibitory activity.

[0201] Table 3 IC50 and anti-tumor cell proliferation activity test results of some compounds with good inhibitory activity against CDK2 kinase

[0202]

[0203] The results of the cell anti-proliferation experiment were consistent with the results of the kinase inhibition activity, and were basically positively correlated. That is, compounds with a good inhibitory effect on CDK2-cyclin E kinase also had a strong proliferation inhibition activity on tumor cells; this indirectly verified that inhibiting CDK2 activation can inhibit cell proliferation and achieve an anti-tumor effect. The tested compounds had varying degrees of cell proliferation inhibition on both tumor cells, among which Example 17 (IC 50 =1.93 μM, 2.57 μM), Example 21 (IC 50 =1.62 μM, 1.95 μM) and Example 22 (IC 50 =3.43 μM, 1.17 μM) showed strong anti-proliferative activity against human rectal cancer cells HCT 116 and human myelomonocytic leukemia cells MV4-11.

[0204] Although the present invention has been described by way of specific embodiments, it should not be construed as being limited thereto; rather, the present invention encompasses the general aspects disclosed hereinabove. Various modifications and embodiments are possible without departing from the spirit and scope of the present invention.

Claims

1. A pteridine 7(8H)-one compound having a structure represented by the general formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof, The pteridine 7(8H)-ketone compound of the structure represented by the general formula (I) is selected from the following structures:

2. The pteridine 7(8H)-one compound or its stereoisomer or its pharmaceutically acceptable salt according to claim 1, characterized in that: The pharmaceutically acceptable salts include potassium salt, sodium salt, hydrochloride, formates, trifluoroacetates, phosphates and sulfates.

3. A pharmaceutical composition, characterized in that A pteridine 7(8H)-one compound or a stereoisomer thereof or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 2.

4. The pharmaceutical composition according to claim 3, characterized in that Pharmaceutically acceptable excipients are also included.

5. The pharmaceutical composition according to claim 4, characterized in that The pharmaceutically acceptable excipients include diluents, excipients, fillers, binders, wetting agents, and absorption enhancers.

6. Use of the pteridine compound or its stereoisomer or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 2 in the preparation of a medicament for preventing or treating cancer.

7. The use according to claim 6, characterized in that: Cancers include: Breast cancer, colon cancer, rectal cancer, kidney cancer, epidermal cancer, liver cancer, lung cancer, esophageal cancer, gallbladder cancer, ovarian cancer, pancreatic cancer, stomach cancer, cervical cancer, thyroid cancer, nasal cancer, head and neck cancer, prostate cancer, skin cancer, myeloid hematopoietic cell tumors, thyroid follicular cancer, tumors originating from stromal cells, central or peripheral nervous system tumors, melanoma, glioma, seminoma, teratoma, osteosarcoma, xeroderma pigmentosum, keratoacanthoma, thyroid follicular cancer, Kaposi sarcoma.